Led · Seed · Apr 2026

Founded in 2025 by Eno Thereska (CEO), Neil Lawrence (chief scientist), and Zhenwen Dai (CTO), Trent AI offers a multi-agent security product designed to continuously scan environments, assess risk, mitigate vulnerabilities, and evaluate overall security posture for AI agents. The founders come from Amazon/AWS and Spotify engineering backgrounds and academic research. The company positions its product as the first multi-agent security solution for evolving agentic systems, targeting developers and security teams deploying autonomous workflows. Early customers and design partners include Canopy and Weblogic, which reported improved visibility into security posture, security audit reports, fast vulnerability identification, clear remediation scopes, and adaptive feedback. Financially, the company has announced a $13M seed round to accelerate product development, hire engineering talent, and expand its customer base.

Participated · Series A · Mar 2026

Immutrin is developing a novel antibody intended to selectively bind amyloid fibrils and trigger immune-mediated depletion of established amyloid deposits. Its lead program is focused on ATTR cardiomyopathy, with the company positioning the asset as potentially best-in-class for amyloid removal and noting possible applicability to other amyloidosis types. The company was co-founded by Cambridge Innovation Capital and academics Professor Sir Mark Pepys, Sir Gregory Winter and Professor Daniel Christ and is headquartered in Cambridge, UK. Immutrin recently raised £65 million ($87 million) in a Series A to fund its lead asset through clinical proof of concept. Management includes CEO Mihriban Tuna and new CFO/COO Tolga Hassan, and the board will include representatives from Frazier, F-Prime, Qiming and Cambridge Innovation Capital. The company emphasizes its scientific foundation based on decades of work on amyloid biology and antibody engineering.

Led · Seed · Feb 2026

BeyondMath is a London-based deep-tech firm founded in 2022 by AI veterans Alan Patterson and Darren Garvey to create what it calls the world’s largest foundational physics model. Trained directly on first-principles physics, the platform lets engineering teams generate high-fidelity simulations of aerodynamics, thermal management, and other complex phenomena in minutes instead of hours or days. Early customers span automotive, aerospace, and electronics manufacturers, and the company has formed technical partnerships with NVIDIA and AWS. Management claims the technology can be a “ChatGPT moment for physics,” unlocking faster, more sustainable product design across multiple industries. With fresh capital in hand, BeyondMath plans to double headcount, scale commercial deployments, and expand its customer base across Europe, the United States, and Japan. The company has secured $18.5 million in total seed funding to date to support these growth initiatives.

Participated · Series A · Nov 2025

Spun out of the University of Cambridge, T-Therapeutics leverages its proprietary OpTiMus discovery platform to create TCR-CD3 bispecific drugs that precisely target pathogenic immune cells. Its lead oncology candidate addresses a pan-tumour driver target applicable across multiple solid tumours, while its lead immunology program is a pan-autoimmune bispecific designed to reset the immune system by selectively depleting harmful T-cell subsets. The company is also exploring new therapeutic strategies such as T-cell subset depletion to broaden its clinical impact. Management is headed by CEO Theodora Harold. To date, T-Therapeutics has secured a total of $91 million in Series A financing, providing runway to advance its pipeline toward first-in-human studies. The fresh capital is earmarked for moving these programs into the clinic and expanding discovery efforts across oncology and autoimmune indications.

Led · Seed · Mar 2025

TRIMTECH Therapeutics was founded on academic research into the E3-ligase TRIM21 and has developed two proprietary targeted protein degradation platforms, TRIMTAC and TRIMGLUE. The company focuses on small-molecule degraders designed to selectively remove toxic protein aggregates and oligomers while sparing functional monomeric protein. TRIMTECH is advancing CNS-penetrant degrader candidates aimed at neurodegenerative diseases with large patient populations. Its current financial position includes a seed financing round totaling $47M following a $14M extension led by JJDC and BGF. The new capital is earmarked to progress its platforms and expand the company's portfolio, and JJDC and BGF will each take board seats as non-executive directors. TRIMTECH is based in Cambridge, England.